Perampanel (PER) is an adjunctive treatment option for focal epileptic seizures with or without secondary generalization in patients with epilepsy aged ≥4 years and for primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy aged ≥7 years (EU) or ≥12 years (USA). In the USA PER can also be prescribed as monotherapy for focal epileptic seizures. It was first approved in Europe and the USA in 2012. PER is a selective non-competitive antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors.
5
DIC
DIC
0